Company: ARAI
Filing Date: 2025-06-17
Form Type: S-1
Source: 0001641172-25-015428
Chunk: 29

Company: Arrive AI Inc.
Filing Date: 2025-06-17
Form: S-1
Chunk 29
---
 technology and services to market with an
initial focused market target of medical operations such as hospitals, labs, clinic, doctors, pharmacies, and large assisted living businesses,
which will then further expand to other market segments as we aim to eventually achieve ubiquity and business and residential density
necessary for a future of pervasive automated logistics for everyone; we will use methods initially such as direct sales; automation
partners as channel sales, tradeshows, publicized innovation research and projects with bellwether customers, white-papers, and targeted
digital marketing campaigns and organic (search engine optimization, blogs). In the event we are not successful in obtaining a significant
volume of early strategic innovation customers’ orders for our products and services, then we will face significant obstacles in
expanding our business into an early adopters and mainstream market where the majority of future revenue would come from. We cannot give
any assurance that our marketing efforts will be successful. If they are not, revenue may not be sufficient to cover our fixed costs
and we may not become profitable.

We may engage in transactions with businesses that may be affiliated with our officers, directors or significant stockholders, and which may involve actual or potential conflicts of interest.

We may decide to make investments in one or more
businesses affiliated with our officers, directors or significant stockholders. Such investment opportunities may compete with other
opportunities for our investment dollars. Although we will not specifically focus on, or target, any particular transaction with any
affiliates or affiliated entities, we would pursue such a transaction if we determined that such an affiliated investment was attractive
from a risk-adjusted return perspective, and such transaction were approved by a majority of our independent and disinterested directors.
Any such activity would involve actual or potential conflicts of interest. Although we are confident that we can navigate these conflicts
consistent with best practices and applicable law, the existence or appearance of such conflicts of interest could make our publicly
traded securities less attractive and thereby reduce their trading prices.

The ongoing conflict between Ukraine and Russia could adversely affect our business, consolidated financial condition, and results of operations.

Russia’s military actions against Ukraine
have led to an unprecedented expansion of export restrictions and sanctions imposed by the United States, the European Union, the
United Kingdom, and numerous other countries against Russia and Belarus. In addition, Russian authorities have imposed significant currency
control measures, other sanctions, and imposed other economic and financial restrictions. The situation continues to evolve, and further
sanctions and export restrictions could negatively impact the